Issue Type: Payer and Supply Chain Economics Favor Higher Cost Drugs
in challenge narrative
-
Impact of President Trump’s Proposed 340B Hospital Eligibility Threshold
-
Does the 6% in Medicare Part B Drug Reimbursement Affect Prescribing?
-
Association of Rebates in Part D with Patient OOP and Federal Spending
-
Reforming the Payment System for Medical Oncology
-
Limits on Medicare’s Ability to Control Rising Spending on Cancer Drugs